Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
TSMC Gradually Restarts Japan Chip Plant After Kumamoto Earthquake 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
(4) - EconoTimes)
SOUTH SAN FRANCISCO, Calif., May 07, 2018 -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported the grant of inducement awards to Deitmar Berger effective as of May 7, 2018.
The compensation committee of Atara's board of directors granted Dr. Berger a stock option to purchase 85,000 shares of Atara’s common stock, and restricted stock units to acquire 50,000 shares of Atara’s common stock. The stock option and restricted stock units were granted as an inducement material to Dr. Berger entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option has a seven-year term and an exercise price of $42.05, equal to the per share closing price of Atara's common stock as reported by Nasdaq on May 7, 2018. The awards vest over four years, with 25% vesting on the first anniversary of the grant date and the remainder vesting over the following three years, assuming the employee is continuously employed by Atara as of such vesting dates.
Atara is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. (@Atarabio) is a leading T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. The Company's off-the-shelf, allogeneic T-cells are bioengineered from donors with healthy immune function and allow for rapid delivery from inventory to patients without a requirement for pretreatment. Atara's T-cell immunotherapies are designed to precisely recognize and eliminate cancerous or diseased cells without affecting normal, healthy cells.
INVESTOR & MEDIA CONTACTS:
Investors:
John Craighead, Atara Biotherapeutics
650-410-3012
[email protected]
Steve Klass, Burns McClellan
212-213-0006 x331
[email protected]
Media:
Justin Jackson, Burns McClellan
212-213-0006 x327
[email protected]
